Several studies investigating target genes such as EGFR, MET, and fibroblast growth factor receptor (FGFR) have been conducted since the application of trastuzumab in the treatment of HER2-positive gastric cancer patients [11, 15–17]. Here, ERBB2 is linked to gastric cancer.